BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21437624)

  • 1. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
    Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
    Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome.
    Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; França JB; Ferriani RA; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):211-6. PubMed ID: 22510229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
    Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
    Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
    Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
    Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
    J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.
    Lewandowski KC; Komorowski J; Mikhalidis DP; Bienkiewicz M; Tan BK; O'Callaghan CJ; Lewinski A; Prelevic G; Randeva HS
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3123-30. PubMed ID: 16705077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
    Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
    Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
    Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
    Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
    Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
    Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.